Translational control of tumor immune escape via the eIF4F–STAT1–PD-L1 axis in melanoma

Translation initiation factors and their relevance in cancer

(2018) Columba de la Parra et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

Eukaryotic initiation factor 4F — sidestepping resistance mechanisms arising from expression heterogeneity

(2018) Jennifer Chu et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA

(2017) Matthew A. Coelho et al.   IMMUNITY

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators

(2017) Riccardo Mezzadra et al.   NATURE

CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity

(2017) Marian L. Burr et al.   NATURE

RAF proteins exert both specific and compensatory functions during tumour progression of NRAS-driven melanoma

(2017) Coralie Dorard et al.   Nature Communications

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

(2017) Angel Garcia-Diaz et al.   Cell Reports

Deubiquitination and Stabilization of PD-L1 by CSN5

(2016) Seung-Oe Lim et al.   CANCER CELL

Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade

(2016) Joseph L. Benci et al.   CELL

Synergistic effects of eIF4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell lines

(2016) Hélène Malka-Mahieu et al.   CELL CYCLE

Developing anti-neoplastic biotherapeutics against eIF4F

(2016) Jutta Steinberger et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Molecular Pathways: The eIF4F Translation Initiation Complex—New Opportunities for Cancer Treatment

(2016) Hélène Malka-Mahieu et al.   CLINICAL CANCER RESEARCH

Too Much of a Good Thing? Chronic IFN Fuels Resistance to Cancer Immunotherapy

(2016) James L. Reading et al.   IMMUNITY

What does PD-L1 positive or negative mean?

(2016) Antoni Ribas et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

MYC regulates the antitumor immune response through CD47 and PD-L1

(2016) S. C. Casey et al.   SCIENCE

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

Translation Initiation Factors: Reprogramming Protein Synthesis in Cancer

(2016) Jennifer Chu et al.   TRENDS IN CELL BIOLOGY

CRISPR-Mediated Drug-Target Validation Reveals Selective Pharmacological Inhibition of the RNA Helicase, eIF4A

(2016) Jennifer Chu et al.   Cell Reports

Targeting the eIF4A RNA helicase as an anti-neoplastic approach

(2015) Jennifer Chu et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

Targeting the eIF4F Translation Initiation Complex: A Critical Nexus for Cancer Development

(2015) J. Pelletier et al.   CANCER RESEARCH

Targeting the translation machinery in cancer

(2015) Mamatha Bhat et al.   NATURE REVIEWS DRUG DISCOVERY

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumour-derived SPARC drives vascular permeability and extravasation through endothelial VCAM1 signalling to promote metastasis

(2015) Mélanie Tichet et al.   Nature Communications

The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease

(2015) John T. Patton et al.   Oncotarget

RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer

(2014) Andrew L. Wolfe et al.   NATURE

eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies

(2014) Lise Boussemart et al.   NATURE

Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade

(2014) Z. A. Cooper et al.   Cancer Immunology Research

Evidence for a Functionally Relevant Rocaglamide Binding Site on the eIF4A–RNA Complex

(2013) Heather Sadlish et al.   ACS Chemical Biology

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Targeting Synthetic Lethal Interactions between Myc and the eIF4F Complex Impedes Tumorigenesis

(2012) Chen-Ju Lin et al.   Cell Reports

Formation of the eIF4F Translation-Initiation Complex Determines Sensitivity to Anticancer Drugs Targeting the EGFR and HER2 Receptors

(2011) P. Zindy et al.   CANCER RESEARCH

Efficient Suppression of Gene Expression by Targeting 5′-UTR-Based RNA Quadruplexes with Bisquinolinium Compounds

(2011) Kangkan Halder et al.   CHEMBIOCHEM

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma

(2010) M. R. Green et al.   BLOOD

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oncogenic Braf Induces Melanocyte Senescence and Melanoma in Mice

(2009) Nathalie Dhomen et al.   CANCER CELL

In Vitro and In Vivo Anti-Melanoma Effects of Ciglitazone

(2009) Thomas Botton et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Antitumor Activity and Mechanism of Action of the Cyclopenta[b]benzofuran, Silvestrol

(2009) Regina Cencic et al.   PLoS One

Translational control of the innate immune response through IRF-7

(2008) Rodney Colina et al.   NATURE